Literatur
-
1
The National Institute of Child Health and Human
Developments Intravenous Immunoglobulin Study Group .
Intravenous immune globulin for the prevention of bacterial
infections in children with symptomatic human immunodeficiency virus
infection.
N Engl J
Med.
1991;
325
73-80
-
2
The American Society of Hematology ITP Practice Guideline
Panel .
Diagnosis and treatment of idiopathic thrombocytopenic
purpura: recommendations of the American Society of Hematology.
Ann
Intern
Med.
1997;
126
319-326
-
3
Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome
Trial Group .
Randomised trial of plasma exchange, intravenous
immunoglobulin, and combined treatments in Guillain-Barre
syndrome.
Lancet.
1997;
349
225-230
-
4
Achiron A, Gabbay U, Gilad R. et al .
Intravenous immunoglobulin treatment in multiple sclerosis.
Effect on
relapses.
Neurology.
1998;
50
398-402
-
5
Alejandria M M, Lansang M A, Dans L F, Mantaring J B.
Intravenous immunoglobulin for treating sepsis and septic
shock.
Cochrane Database Syst
Rev.
2002;
CD001090
-
6
Azulay J P, Blin O, Pouget J. et al .
Intravenous immunoglobulin treatment in patients with motor
neuron syndromes associated with anti-GM1 antibodies: a double-blind,
placebo-controlled
study.
Neurology.
1994;
44
429-432
-
7
Barron K S, Murphy D J, Silverman E D. et al .
Treatment of Kawasaki syndrome: a comparison of two dosage
regimens of intravenously administered immune globulin.
J
Pediatr.
1990;
117
638-644
-
8
Blanchette V, Imbach P, Andrew M. et al .
Randomised trial of intravenous immunoglobulin G, intravenous
anti-D, and oral prednisone in childhood acute immune thrombocytopenic
purpura.
Lancet.
1994;
344
703-707
-
9
Blanchette V S, Luke B, Andrew M. et al .
A prospective, randomized trial of high-dose intravenous
immune globulin G therapy, oral prednisone therapy, and no therapy in childhood
acute immune thrombocytopenic purpura.
J
Pediatr.
1993;
123
989-995
-
10
Bril V, Ilse W K, Pearce R, Dhanani A, Sutton D, Kong K.
Pilot trial of immunoglobulin versus plasma exchange in
patients with Guillain-Barre
syndrome.
Neurology.
1996;
46
100-103
-
11
Busse P J, Razvi S, Cunningham-Rundles C.
Efficacy of intravenous immunoglobulin in the prevention of
pneumonia in patients with common variable immunodeficiency.
J
Allergy Clin
Immunol.
2002;
109
1001-1004
-
12
Dalakas M C, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B.
High-dose intravenous immune globulin for stiff-person
syndrome.
N Engl J
Med.
2001;
345
1870-1876
-
13
Dalakas M C, Illa I, Dambrosia J M. et al .
A controlled trial of high-dose intravenous immune globulin
infusions as treatment for dermatomyositis.
N Engl J
Med.
1993;
329
1993-2000
-
14
Dalakas M C, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E.
A controlled study of intravenous immunoglobulin combined
with prednisone in the treatment of
IBM.
Neurology.
2001;
56
323-327
-
15
Dybul M, Fauci A S, Bartlett J G, Kaplan J E, Pau A K.
Guidelines for using antiretroviral agents among HIV-infected
adults and adolescents.
Ann Intern
Med.
2002;
137
381-433
-
16
Dyck P J, Litchy W J, Kratz K M. et al .
A plasma exchange versus immune globulin infusion trial in
chronic inflammatory demyelinating polyradiculoneuropathy.
Ann
Neurol.
1994;
36
838-845
-
17
Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Austrian Immunoglobulin in Multiple Sclerosis Study
Group .
Randomised placebo-controlled trial of monthly intravenous
immunoglobulin therapy in relapsing-remitting multiple
sclerosis.
Lancet.
1997;
349
589-593
-
18
Federico P, Zochodne D W, Hahn A F, Brown W F, Feasby T E.
Multifocal motor neuropathy improved by IVIg: randomized,
double-blind, placebo-controlled
study.
Neurology.
2000;
55
1256-1262
-
19
Feinstein L C, Seidel K, Jocum J. et al .
Reduced dose intravenous immunoglobulin does not decrease
transplant-related complications in adults given related donor marrow
allografts.
Biol Blood Marrow
Transplant.
1999;
5
369-378
-
20
Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Myasthenia Gravis Clinical Study Group .
Clinical trial of plasma exchange and high-dose intravenous
immunoglobulin in myasthenia gravis.
Ann
Neurol.
1997;
41
789-796
-
21
Hahn A F, Bolton C F, Zochodne D, Feasby T E.
Intravenous immunoglobulin treatment in chronic inflammatory
demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over
study.
Brain.
1996;
119
1067-1077
-
22
Howard J F.
Intravenous immunoglobulin for the treatment of acquired
myasthenia
gravis.
Neurology.
1998;
51
S30-S36
-
23
Hundt M, Manger K, Dorner T. et al .
Treatment of acute exacerbation of systemic lupus
erythematosus with high-dose intravenous immunoglobulin.
Rheumatology
(Oxford).
2000;
39
1301-1302
-
24
Kumar R, Ghali A, Ekaldious A W, Mahmoud O I, Al L umai AS.
Post-transfusion purpura: case report.
Ann
Hematol.
2001;
80
488-491
-
25
Laupland K B, Dele D H.
Epidemiology, etiology, and management of Kawasaki disease:
state of the art.
Pediatr
Cardiol.
1999;
20
177-183
-
26
Lederman H M, Winkelstein J A.
X-linked agammaglobulinemia: an analysis of 96
patients.
Medicine
(Baltimore).
1985;
64
145-156
-
27
Leger J M, Chassande B, Musset L, Meininger V, Bouche P, Baumann N.
Intravenous immunoglobulin therapy in multifocal motor
neuropathy: a double-blind, placebo-controlled
study.
Brain.
2001;
124
145-153
-
28
Levy J, Espanol-Boren T, Thomas C. et al .
Clinical spectrum of X-linked hyper-IgM syndrome.
J
Pediatr.
1997;
131
47-54
-
29
Mendell J R, Barohn R J, Freimer M L. et al .
Randomized controlled trial of IVIg in untreated chronic
inflammatory demyelinating
polyradiculoneuropathy.
Neurology.
2001;
56
445-449
-
30
Mofenson L M, Moye J , Korelitz J, Bethel J, Hirschhorn R, Nugent R. The National Institute of Child Health and Human
Development Intravenous Immunoglobulin Clinical Trial Study Group .
Crossover of placebo patients to intravenous immunoglobulin
confirms efficacy for prophylaxis of bacterial infections and reduction of
hospitalizations in human immunodeficiency virus-infected
children.
Pediatr Infect Dis
J.
1994;
13
477-484
-
31
Newburger J W, Takahashi M, Burns J C. et al .
The treatment of Kawasaki syndrome with intravenous gamma
globulin.
N Engl J
Med.
1986;
315
341-347
-
32
Nydegger U E.
Sepsis and polyspecific intravenous
immunoglobulins.
J Clin
Apheresis.
1997;
12
93-99
-
33
Prins C, Kerdel F A, Padilla R S. et al .
Treatment of toxic epidermal necrolysis with high-dose
intravenous immunoglobulins: multicenter retrospective analysis of 48
consecutive cases.
Arch
Dermatol.
2003;
139
26-32
-
34
Report of an IUIS Scientific Committee .
Primary Immunodeficiency Diseases.
Clin Exp
Immunol.
1999;
118
1-28
-
35
Schmidt R E, Budde U, Schafer G, Stroehmann I.
High-dose intravenous gammaglobulin for idiopathic
thrombocytopenic
purpura.
Lancet.
1981;
2
475-476
-
36
Sicherer S H, Winkelstein J A.
Primary immunodeficiency diseases in
adults.
JAMA.
1998;
279
58-61
-
37
Sorensen P S, Wanscher B, Jensen C V. et al .
Intravenous immunoglobulin G reduces MRI activity in
relapsing multiple
sclerosis.
Neurology.
1998;
50
1273-1281
-
38
Stangel M, Hartung H P.
Intravenous immunoglobulins in multiple sclerosis. Studies
and mechanisms of action - an
update.
Nervenarzt.
2002;
73
119-124
-
39
Sullivan K M, Storek J, Kopecky K J. et al .
A controlled trial of long-term administration of intravenous
immunoglobulin to prevent late infection and chronic graft-vs.-host disease
after marrow transplantation: clinical outcome and effect on subsequent immune
recovery.
Biol Blood Marrow
Transplant.
1996;
2
44-53
-
40
Sultan Y, Kazatchkine M D, Nydegger U, Rossi F, Dietrich G, Algiman M.
Intravenous immunoglobulin in the treatment of spontaneously
acquired factor VIII:C inhibitors.
Am J
Med.
1991;
91
35S-39S
-
41
Uchino H, Yasunaga K, Akatsuka J.
A cooperative clinical trial of high-dose immunoglobulin
therapy in 177 cases of idiopathic thrombocytopenic purpura.
Thromb
Haemost.
1984;
51
182-185
-
42
Van den Berg L H, Kerkhoff H, Oey P L. et al .
Treatment of multifocal motor neuropathy with high dose
intravenous immunoglobulins: a double blind, placebo controlled
study.
J Neurol Neurosurg
Psychiatry.
1995;
59
248-252
-
43
van der Meche F G, Schmitz P I. Dutch Guillain-Barre Study Group .
A randomized trial comparing intravenous immune globulin and
plasma exchange in Guillain-Barre syndrome.
N Engl J
Med.
1992;
326
1123-1129
-
44
van Doorn P A, Brand A, Strengers P F, Meulstee J, Vermeulen M.
High-dose intravenous immunoglobulin treatment in chronic
inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled,
crossover
study.
Neurology.
1990;
40
209-212
-
45
Viard I, Wehrli P, Bullani R. et al .
Inhibition of toxic epidermal necrolysis by blockade of CD95
with human intravenous
immunoglobulin.
Science.
1998;
282
490-493
-
46
Werdan K.
Intravenous immunoglobulin for prophylaxis and therapy of
sepsis.
Curr Opin Crit
Care.
2001;
7
354-361
-
47
Winston D J, Antin J H, Wolff S N. et al .
A multicenter, randomized, double-blind comparison of
different doses of intravenous immunoglobulin for prevention of
graft-versus-host disease and infection after allogeneic bone marrow
transplantation.
Bone Marrow
Transplant.
2001;
28
187-196
Dr. med. Hans Heiken
Prof. Dr. med. Reinhold E. Schmidt
Abteilung Klinische Immunologie, Medizinische Hochschule
Hannover
Carl-Neuberg-Straße 1
30625 Hannover
Email: Heiken.Hans@MH-Hannover.de
Email: Immunologie@MH-Hannover.de
